Mode of Action

Cell to Cure’s ASC product helps repair and regenerate tissue by signaling to other cells, interacting with the immune system, and supporting natural repair processes.

Renegerative Cell Therapy

The mode of action of our product is multifaceted and involves both direct and indirect effects.

Being multipotent allogeneic adipose tissue-derived mesenchymal stromal/stem cells (ASCs), our product is by nature capable of differentiating into other cell types, but the therapeutic action of our ASC product is considered driven by paracrine (cell to cell) signalling, interaction with cells from the immune system, and support of endogenous repair mechanisms, rather than direct cell replacement.

Interactions between the ASCs and diseased tissues induce the release of a wide range of factors secreted from the ASCs, the immune system and the adjacent tissue.

This simultaneous activation of multiple regenerative pathways initiates processes such as regulation of the immune system, reduced inflammation, growth of new blood vessels, and reduced fibrosis, jointly contributing to tissue repair and regeneration.

ASC Mechanisms

Secrete bioactive molecules including cytokines, growth factors, and extracellular vesicles
Exert immunoregulatory effects
- Interact with both the innate and adaptive immune system
- Inhibit proliferation and function of pro-inflammatory responder cells
- Reduce pro-inflammatory cytokines
- Promote regulatory cells and anti-inflammatory cytokines

Promote angiogenesis/neovascularisation (formation of new blood vessels)
Exert modulation of tissue extracellular matrix
Support repair by homing to sites of injury or inflammation
Elicit minimal immune response, making them suitable for donor-derived therapies

Latest Publications

See All Publications

2025 March

Allogeneic mesenchymal stromal cell therapy on primary graft dysfunction after lung transplantation

Clinical

2025 March

Long-term Effectiveness and Safety of Mesenchymal Stromal Cell Therapy for Radiation-Induced Hyposalivation in Head and Neck Cancer Survivors: A Randomized Phase II Trial

Clinical

2024 December

Mesenchymal stromal cells to treat patients with non-ischaemic heart failure: Results from SCIENCE II pilot study

Clinical

2024 June

Long-Term Outcome Following Treatment With Allogeneic Mesenchymal Stem/Stromal Cells for Radiation-Induced Hyposalivation and Xerostomia

Clinical

2024 June

Investigating the paracrine and juxtacrine abilities of adipose-derived stromal cells in angiogenesis triple cell co-cultures

Productions & Pre-clinical

2024 May

Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase II Randomized, Placebo-Controlled Trial

Clinical

2024 January

Allogeneic mesenchymal stem cell therapy for dry eye disease in patients with Sjögren’s syndrome: A randomized clinical trial

Clinical

2023 April

Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction – the SCIENCE trial

Clinical

2023 April

Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure

Clinical

2022 December

Optimizing an immunomodulatory potency assay for Mesenchymal Stromal Cell

Productions & Pre-clinical

2022 December

Intraglandular mesenchymal stem cell treatment induces changes in the salivary proteome of irradiated patients

Clinical

2022 September

Functional in vitro models of the inhibitory effect of adipose tissue-derived stromal cells on lymphocyte proliferation: Improved sensitivity and quantification through flow cytometric analysis

Productions & Pre-clinical

2022 June

GMP Compliant Production of a Cryopreserved Adipose-Derived Stromal Cell Product for Feasible and Allogeneic Clinical Use

Productions & Pre-clinical

2022 June

Adipose-derived stromal cells increase the formation of collagens through paracrine and juxtacrine mechanisms in a fibroblast co-culture model utilizing macromolecular crowding

Productions & Pre-clinical

2022 May

Intraglandular Off-the-Shelf Allogeneic Mesenchymal Stem Cell Treatment in Patients with Radiation-Induced Xerostomia: A Safety Study (MESRIX-II)

Clinical

2021 October

The Initial Cardiac Tissue Response to Cryopreserved Allogeneic Adipose Tissue-Derived Mesenchymal Stromal Cells in Rats with Chronic Ischemic Cardiomyopathy

Productions & Pre-clinical

2021 January

Safety and feasibility of mesenchymal stem cell therapy in patients with aqueous deficient dry eye disease

Clinical

2020 October

Adipose Tissue-Derived Stromal Cells Induce a Highly Trophic Environment While Reducing Maturation of Monocyte-Derived Dendritic Cells

Productions & Pre-clinical

2018 July

Development of large-scale manufacturing of adipose-derived stromal cells for clinical applications using bioreactors and human platelet lysate

Productions & Pre-clinical

2017 November

Cryopreserved Off-the-Shelf Allogeneic Adipose-Derived Stromal Cells for Therapy in Patients with Ischemic Heart Disease and Heart Failure – A Safety Study

Clinical

2017 January

Senescence and quiescence in adipose-derived stromal cells: Effects of human platelet lysate, fetal bovine serum and hypoxia

Productions & Pre-clinical

2016 November

Culture expansion of adipose derived stromal cells. A closed automated Quantum Cell Expansion System compared with manual flask-based culture

Productions & Pre-clinical

2016 January

Comparison of clinical grade human platelet lysates for cultivation of mesenchymal stromal cells from bone marrow and adipose tissue

Productions & Pre-clinical